There is increasing evidence that environmental factors in fetal life can affect a person's susceptibility to asthma and allergic diseases. 1 Particular focus has been on maternal intake of the long-chain n-3 polyunsaturated fatty acids (PUFAs) eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3), which are abundant in seafood and fish oil. EPA and DHA can affect function of the fetal immune system through several anti-inflammatory mechanisms. Fatty acids cross the placenta, 2 and EPA and DHA might directly affect the development of the fetal immune system by influencing cell signaling and gene expression, competing with arachidonic acid for cyclooxygenase and lipoxygenase enzymes to produce less potent eicosanoids, and through production of anti-inflammatory resolvins. [3] [4] [5] This in turn might result in a reduced T H 2 allergic immune response, 6 which has been substantiated in 2 previous randomized controlled trials (RCTs) with maternal fish oil supplementation, leading to reduced formation of cytokines produced by T H 2 cells at birth. [7] [8] [9] Furthermore, maternal fish oil supplementation had a beneficial effect on skin sensitization and IgE-related allergic diseases in infants up to 12 months. 10 In 2008, Olsen et al 11 published results from the first randomized placebo-controlled trial that investigated the long-term effect of fish oil supplementation in late pregnancy, and they reported a beneficial effect on offspring asthma discharge diagnoses from a mandatory national patient register. However, because only patients seen in hospitals are reported to the patient register, 12 asthma discharge diagnoses from this register are known to underestimate the true occurrence of asthma in the general population. Therefore in the same RCT we decided to extend the analyses with methods of asthma and allergic respiratory disease ascertainment that are more relevant for the general population and with follow-up up until 24 years of age. Our aim was to determine whether our previously reported reduced occurrence of asthma discharge diagnoses in offspring whose mothers had taken fish oil in pregnancy could be extended to a more varied phenotype that also included mild and moderate manifestations of allergic respiratory disease and might be more important for disease prevention on a population level.
METHODS

Study cohort
The Aarhus Trial recruited 533 Danish pregnant women (61% of those eligible) with singleton pregnancies through antenatal care clinics in 1990. The women were block randomized in the ratio 2:1:1 stratified by parity to 3 groups who received a daily supplementation of either fish oil, olive oil, or no oil from gestational week 30 until delivery. The study design and original aim have been described in detail elsewhere.
14 Briefly, 266 women were randomized to the intervention group and received four 1-g gelatin capsules with fish oil (32% EPA, 23% DHA, and 2 mg of tocopherol/mL; Pikasol, Lube Ltd, Hadsund, Denmark) daily, corresponding to 2.7 g/d long-chain n-3 PUFAs. An additional 136 women were randomized to the placebo group and given 4 similar-looking 1-g capsules with olive oil (72% oleic acid [18:1n-9] and 12% linoleic acid [18:2n-6]) per day. Women allocated to the 2 oil capsule groups and the study coordinators were blinded to treatment allocation. A third group of 131 women were randomized to receive no oil capsules but were informed about the purpose of the trial and the potential beneficial effects of supplementation with long-chain n-3 PUFAs, thus acting as a passive-intervention positive control group. Active fish oil supplementation was associated with longer gestation 14 when compared with placebo, and it increased maternal EPAderived thromboxane and prostacyclin production 15 and increased the concentrations of long-chain n-3 PUFAs in umbilical blood and tissues 16 and in early breast milk 17 when compared against a combination of both control groups. In 2008-2009, a follow-up of the 18-to 19-year-old offspring of originally enrolled mothers was undertaken. At that time, 517 (97%) mother-child dyads were still alive and living in Denmark. An overview of the original trial and the follow-up is presented in Fig 1 . 
Register-based outcomes
We assessed cases of asthma medication use from the national prescription register, which holds information on all prescriptions filled in Danish pharmacies written by doctors from all levels of the health care sector. 18 This allows for complete follow-up of all subjects remaining within the country over their lifetime. We were able to follow-up 522 (98%) of the 533 subjects born to women in the trial; the remaining 11 subjects were lost to follow-up because of emigration. We used Anatomical Therapeutic Chemical classification system codes R03A, R03B, R03C, and R03D for asthma and R01AC, R01AD, R01AX, R06A, S01GA, and S01GX for allergic rhinitis.
We defined cases of asthma medication by using a modified validated definition 19 of those who had filled 2 or more prescriptions for b 2 -agonists or steroids or 1 or more prescriptions for leukotriene receptor antagonists. Patients with allergic rhinitis were defined as those having filled 2 or more allergic rhinitis prescriptions, including eye drops, nasal decongestants, and oral antihistamines. The capture time was from the start of the register in 1995 until the end of 2014.
As in our previous report, 11 we also identified patients with a discharge diagnosis of asthma from the national patient register. Follow-up was extended by 7 years relative to our previous report through the end 
Self-reported outcomes
In 2008, at approximately 18 years of age, 382 (72%) offspring completed a self-administered Web-based questionnaire with 4 questions on asthma and hay fever that followed the International Studies on Asthma and Allergies in Childhood core questionnaire. 21 Based on answers to this questionnaire, we identified subjects reporting ''ever doctor diagnosed asthma,'' ''ever doctor diagnosed hay fever,'' ''current asthma medication use,'' and ''current hay fever symptoms.''
Analytic strategy
We decided a priori to base the evaluation of the effects of fish oil on the comparison between the fish oil group and the olive oil group because these groups consisted of a double-blind administration of oil capsules. Therefore our main analyses included 396 mother-offspring pairs, 262 from the fish oil group and 134 from the olive oil group. This decision is supported by data collected postpartum and discussed in detail elsewhere, 11 showing that randomization between the 2 blind arms worked well, that olive oil was provided in isocaloric amounts to fish oil, and that the dose of olive oil could reasonably be assumed to be inert in relation to the outcome under study. In contrast, the no oil group was unblinded, was informed of the objectives of the study and the potential health benefits of fish consumption, and had comparable effects on gestation length as seen in the active intervention arm in the original trial.
14 Therefore we considered the no oil arm to represent the effect of a passive intervention consisting of nutritional advice. Comparisons of outcomes between the no oil arm and the active intervention (fish oil) and control (olive oil) arms are presented in Tables E1 and E2 in this article's Online Repository at www.jacionline.org.
Cumulative incidence curves were generated by using the Kaplan-Meier method. In primary intention-to-treat analyses Cox proportional hazards regression analysis was used to estimate the effect of fish oil relative to that of olive oil expressed by hazard ratios (HRs) and 95% CIs; age was used as the J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1 underlying time scale. In the national patient register we followed offspring from birth in 1990 until first asthma discharge diagnosis, death, or end of follow-up in 2013. In the prescription register we followed offspring from 1995, when data became available, until the first occurrence of medication cases, death, or end of follow-up in 2014. The proportional hazards assumption was evaluated by means of visual inspection of residual plots and by using a Wald test for interaction between time and treatment group and was fulfilled in all analyses.
In secondary analyses we used logistic regression models to evaluate the effect of fish oil on self-reported and clinical binary outcomes and calculated odds ratios (ORs) and 95% CIs. For continuous outcomes, we used linear regression models to estimate the mean difference or ratios between geometric means and 95% CIs. Because of the loss to follow-up in these analyses, we could not apply the intention-to-treat principle, and therefore we decided a priori to adjust for offspring sex and maternal smoking as recorded in the interview at enrollment in gestational week 30 because these were the covariates with the strongest association with outcomes in our data.
The following sensitivity analyses were decided on a priori: stratification by offspring sex and adjustment for birth weight and gestational age to investigate whether they could explain the potential effect of fish oil on the outcomes.
All tests were 2-sided, and a P value of less than .05 was considered significant. Analyses were performed with the SAS software package (version 9.3; SAS Institute, Cary, NC).
RESULTS
As reported earlier, 14 the original randomization worked successfully and created similar trial groups with respect to the distribution of covariates (data not shown).
Register-based outcomes
Median ages at first asthma and allergic rhinitis medication use, with register follow-up from 5 to 6 years of age, were 10.5 years (interquartile range, 9.2 years) and 13.8 years (interquartile range, 9.1 years), respectively. For first asthma discharge diagnosis, where register follow-up was available from birth, the corresponding number was 6.2 years (interquartile range, 6.8 years). The probability of having had asthma medication prescribed was significantly reduced in the fish oil group compared with the olive oil group (HR, 0.54; 95% CI, 0.32-0.90; P 5 .02; Table I and Fig 2, B) . For our analyses based on the patient register, we likewise found a reduced probability of asthma discharge diagnosis in the fish oil versus olive oil group (HR, 0.31; 95% CI, 0.13-0.75; P 5.01; Table I and Fig 2, A) , which is in agreement with our previous evaluation with follow-up until age 16 years. The probability of having had allergic rhinitis medication prescribed was also reduced in the fish oil group compared with the olive oil group, but this difference was not statistically significant (HR, 0.70; 95% CI, 0.47-1.05; P 5.09; Table I and Fig 2, C) . Passive intervention had effects similar to those of active intervention (see Tables E1 and E2 ).
Self-reported outcomes, clinical outcomes, and biomarkers
We observed few differences between mother-offspring pairs who participated in the follow-up and those who did not (Table II) , but participation in the clinical examination differed across randomization groups and was lower in the fish oil group (44% vs 55%). In the sample of offspring with self-reported data (Fig 3, A , and see Table E3 in this article's Online Repository at www.jacionline.org), we found lower odds of current asthma medication use (OR, 0.34; 95% CI, 0.12-0.99; P 5 .049) in the fish oil group compared with the olive oil group after adjustment for a priori selected confounders. For a doctor's diagnosis of asthma and hay fever and current hay fever symptoms, odds were also lower in the fish oil group, but these differences were not statistically significant. We did not observe any significant differences between the fish oil and olive oil groups in lung function measurements or levels of total IgE, specific IgE, or eosinophil cationic protein among subjects presenting to the clinical evaluation (Fig 3, B and C, and see Table E3 ). Allergic sensitization with the secondary cutoff of 1.00 KU A /L appeared to be less frequent in the fish oil group compared with the olive oil group (OR, 0.55; 95% CI, 0.28-1.10; P 5 .09). When examining asthma phenotypes, there was a significant effect on allergic asthma (OR, 0.27; 95% CI, 0.08-0.91; P 5 .03), whereas there was no significant effect on nonallergic asthma (OR, 0.49; 95% CI, 0.17-1.37; P 5 .17), although both estimates were in the same direction.
Stratification by offspring sex did not indicate differential effects for boys and girls (data not shown). Birth weight and gestational age did not explain the effect of fish oil on the outcomes (see Table E4 in this article's Online Repository at www.jacionline.org).
DISCUSSION
Fewer children in the fish oil group compared with the olive oil group had been prescribed asthma medication during the 24-year follow-up period. This is in line with our earlier published observation 11 that a smaller proportion of offspring in the fish oil group had been given an asthma discharge diagnosis. The main finding of the present study is that fish oil supplementation not only seems to have prophylactic potential on severe asthma but also on mild-to-moderate asthma, which is a finding of high public health relevance.
There are 3 possible explanations for our findings: (1) fish oil reduced the risk of asthma, (2) olive oil increased the risk of asthma, or (3) a combination of those 2 effects. We believe that the first explanation is most likely. The biological pathways underlying the positive effect of fish oil could be explained by a reduced T H 2 immune response in offspring exposed to long-chain n-3 PUFAs in fetal life. 6 Although olive oil provides linoleic acid, which through elongation and desaturation processes can form arachidonic acid and thereby compete with the n-3 PUFAs, we do not believe that the dosage of 4 g/d could result in any notable effects. In fact, the amount of olive oil in the placebo group provided less than 3% of average daily intake of linoleic acid at that time in Denmark.
14 In contrast, the dosage of EPA and DHA of 2.7 g/d resulted in an approximately 10-fold increase in levels of that nutrient. Several studies from the Mediterranean area, where olive oil is a major dietary component, have associated olive oil with better allergic respiratory outcomes in children, [22] [23] [24] making the second explanation even less likely.
As shown in Tables E1 and E2 , offspring of mothers in the group receiving no oil were remarkably similar to offspring in the fish oil group in terms of the occurrence of asthma and allergic rhinitis. We believe this intriguing finding might be the result of contamination bias. All participants were informed about the study hypothesis relating 2.7 g of long-chain n-3 PUFA supplementation in pregnancy with a reduced risk of preterm birth, and it is possible that those who subsequently did not receive any capsules as part of the trial have self-supplemented or increased their intake of fish during the study period. Data collected postpartum asking about changes in fish intake and self-supplementation revealed such increases were indeed more frequent in the group receiving no oil compared with the olive oil group. It can be argued that a passive intervention informing women about the potential beneficial effects of fish oil might be as effective as actual fish oil supplementation, at least in a group of motivated pregnant women.
A major asset of the national prescription and patient registers is that they cover all citizens in Denmark. This becomes particularly potent in a randomized setting like ours. Because all subjects are included, analyses could be performed on an intention-to-treat basis, and the full scientific advantage of the randomized design for making causal inferences is retained, even in a long-term perspective. As a consequence of this, the observed differences in asthma occurrences across trial groups can, with great certainty, be ascribed to a causal effect of the fish oil compared with olive oil regimens.
The 2 registers have their own characteristic patterns of misclassification. Patients with milder asthma solely treated with asthma medicine prescribed by general practitioners or pediatricians but never admitted to the hospital confer a higher sensitivity to the prescription register. However, this might be at the cost of specificity because asthma medication can be prescribed to clarify a suspected asthma diagnosis. We tried to avoid the latter problem by requiring at least 2 prescriptions for b 2 -agonists and steroids to be counted as a case based on medication HRs were calculated by using Cox regression analysis.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1 data. The fact that analyses based on the 2 different registers agreed in their conclusion, despite different underlying error sources, adds further credibility to the belief that the intervention and placebo groups truly differed in asthma occurrences. Any misclassification with respect to identifying children who truly had or did not have asthma is likely to have occurred to a similar extent across the trial groups and will have tended to attenuate our measures of association rather than create spurious ones. Additional support comes from the self-reported outcomes at 18 to 19 years of age. According to these, the odds of asthma tended Values are presented as means (SDs), medians (25th-75th percentiles), or numbers (percentages). P values were calculated by using x 2 tests, t tests, or the Wilcoxon rank sum test.
to be lower in the fish oil group compared with the olive oil group, although the differences were significant only for current use of asthma medication. In contrast, no effect of fish oil was observed on lung function measures. Clinical follow-up of offspring required active participation, which implied a certain degree of differential attrition. This could potentially have introduced biased estimates if nonparticipants had a different disease risk than participants, but there were no differences in disease occurrence according to register outcomes available for everyone in the cohort (Table II) , making selection bias less likely to explain the results. Rather, the null results for lung function might be due to an influence of current asthma or hay fever medication use at the time of the clinical examination at age 18 to 19 years. Although we asked offspring not to use any medication on the day of the examination, the use of long-acting medications, especially inhaled corticosteroids, in well-treated offspring might have prevented us from detecting any associations with lung function outcomes. Furthermore, we observed no significant effect on parameters reflecting sensitization, such as total and specific IgE levels. It is possible that our ORs, ratios between geometric means, and mean differences with 95% CIs of self-reported (A) and clinical (B and C) outcomes comparing offspring in the fish oil group with those in the olive oil group.
J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 1 study did not have sufficient power to detect any statistical associations with respect to outcomes from the clinical examination in the reduced sample. Remarkably, however, the probability of being prescribed allergic rhinitis medication tended to be lower in the fish oil group compared with the olive oil group, and the effect of fish oil seemed to be strongest on the allergic asthma phenotype, which might still leave uncertainty about a role of allergic sensitization in mediating a possible protective effect of fish oil on asthma. Medication data regarding the first 5 to 6 years of follow-up in the prescription register were lacking, limiting the possibility of investigating common phenotypes of allergic respiratory disease with onset in early childhood. As a result, median age at first occurrence of asthma and allergic rhinitis medication cases was higher compared with median age at first asthma hospitalization, but medication cases continued to develop throughout the entire follow-up period until 24 years of age. Although our data did not enable us to study whether fish oil supplementation was protective against the development of asthma and allergic rhinitis during specific stages of life because of the limited number of cases, our results suggest that fish oil supplementation might have an effect not only on outcomes early in childhood but also on later development of allergic diseases. Other RCTs in the field have focused on early-onset outcomes by assessing allergic disease development up to 3 years of age, and therefore our results are not directly comparable with results from these RCTs. For the most part, previous RCTs have shown favorable effects on immunologic responses at birth [7] [8] [9] and sensitization 25, 26 during the first 12 and 24 months, respectively, but no effects on symptoms of allergic respiratory disease, such as wheezing, allergic rhinitis, or asthma. Perhaps this early effect on immune response and sensitization might later establish itself clinically, as suggested by our results. Therefore long-term follow-up of these RCTs and evaluation of the effect of fish oil supplementation on outcomes occurring later in childhood will be important.
Furthermore, most of the previous RCTs 7, 10, 26 have been conducted in infants with a high hereditary risk of allergic diseases. In contrast, our study was based on a population-based sample, and we did not include measures of family history of allergic diseases. However, because of the randomized design, we would expect the occurrence of allergic diseases in the family to be evenly distributed in the trial groups, and we therefore do not believe that confounding by family history can explain our observed findings. This was indeed supported by questions about maternal and paternal history of asthma and hay fever from the questionnaire completed by the offspring in 2008 from which no differences in the occurrence of family history of allergic disease between the trial groups were seen (data not shown).
In conclusion, results from this RCT showed that offspring whose mothers had taken fish oil in the third trimester of pregnancy had a reduced probability of having had asthma medication prescribed and of receiving an asthma discharge diagnosis during childhood and early adulthood compared with children whose mothers had received olive oil. These results are compatible with the hypothesis that supplementation with longchain n-3 PUFAs late in pregnancy has prophylactic potential in preventing asthma in the offspring. More generally, our results support the hypothesis that the intrauterine environment is critical for the development of asthma not only in childhood but also in a long-term perspective. HRs were calculated by using Cox regression.
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